Challenging Treatment of Disseminated Aspergillosis in a Child With Nephrotic Syndrome

Pediatr Infect Dis J. 2024 Oct 1;43(10):e363-e365. doi: 10.1097/INF.0000000000004422. Epub 2024 Jun 10.

Abstract

Introduction: Central nervous system (CNS) aspergillosis is an opportunistic infection with an increasing incidence and a high mortality rate. It is seen in immunocompromised patients as well as in immunocompetent patients. Here, we present disseminated aspergillosis in a child with nephrotic syndrome treated with long-term and aggressive systemic antifungal treatment and intraventricular (IVent) liposomal amphotericin B (L-AmB) as well as surgical excision and drainage due to difficulty in management.

Case report: A 10-year-old boy with nephrotic syndrome on steroid therapy was admitted with limping and weakness. The cranial magnetic resonance imaging showed multiple intraparenchymal scattered abscesses. The largest one was excised and drained. Abscess culture revealed Aspergillus fumigatus and histopathological examination revealed septate hyphae compatible with Aspergillosis. Intravenous (IV) voriconazole was started, and IV L-AmB was added. The size of lesions and perilesional edema continued to increase, and then IVent L-AmB was added. With IVent and systemic antifungal treatment, regression of the lesions was observed. He was followed up with oral voriconazole and weekly IVent L-AmB. After 2 and a half months, he was re-operated because of increased lesion size, number and perilesional edema, and IV voriconazole and other salvage antifungal therapies were started. Since the lesions had decreased and remained stable, IV voriconazole was switched to oral therapy, and he was followed up as an outpatient. Immunodeficiency diseases were excluded by immunological and genetic tests.

Conclusion: Management of central nervous system aspergillosis can be challenging despite long-term and aggressive systemic and IVent antifungal treatment as well as surgical excision and drainage.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B* / therapeutic use
  • Antifungal Agents* / therapeutic use
  • Aspergillosis / complications
  • Aspergillosis / drug therapy
  • Aspergillosis / microbiology
  • Aspergillus fumigatus* / isolation & purification
  • Child
  • Humans
  • Immunocompromised Host
  • Magnetic Resonance Imaging
  • Male
  • Nephrotic Syndrome* / complications
  • Nephrotic Syndrome* / drug therapy
  • Neuroaspergillosis / drug therapy
  • Treatment Outcome
  • Voriconazole* / therapeutic use

Substances

  • Antifungal Agents
  • Voriconazole
  • Amphotericin B
  • liposomal amphotericin B